Glyco-alteration-based clinical re-evaluation of existing serum biomarkers for ovarian carcinoma
| Project/Area Number |
25830106
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Tumor diagnostics
|
|---|
| Research Institution | Kyoto Sangyo University |
|---|
Principal Investigator |
AKITA Kaoru 京都産業大学, 総合生命科学部, 助教 (10449506)
|
|---|
| Project Period (FY) |
2013-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | 卵巣癌 / 子宮内膜症 / 腫瘍マーカー / 糖鎖 |
|---|
| Outline of Final Research Achievements |
The epithelial ovarian carcinoma (EOC) is an aggressive malignant tumor, and is currently the leading cause of gynecologic cancer death. CA125 is the most commonly used serum marker for EOC, but shows a high-false positive rate for several benign diseases such as endometriosis. The purpose of this study is therefore to identify a useful biochemical tool for detecting qualitative differences between CA125 from patients with endometriosis and EOC, and to facilitate differential diagnosis of these diseases. In this study, we found that the mesothelin-binding ability of serum CA125 was significantly higher in patients with EOC than in patients with endometriosis. Our results suggest that the mesothelin-binding ability may be a useful indicator for qualitatively evaluating CA125 in patients with endometriosis and EOC.
|
Report
(3 results)
Research Products
(4 results)
